Mogroside V Alleviates Lipopolysaccharide-Induced Neuroinflammation via Inhibition of TLR4-MyD88 and Activation of AKT/AMPK-Nrf2 Signaling Pathway

Figure 6

Mog activation of Nrf2 signaling pathway in LPS-treated BV-2 cells. (a) Different added concentrations of Mog (0, 6.25, 12.5, 25, and 50 μM) in BV-2 cells for 2 h, and the proteins expressions of Nrf2, HO-1, GCLC, GCLM, and NQO1 were tested by western blot. (g) BV-2 cells were plated in 6-well plates, preincubated with Mog (0, 6.25, 12.5, and 25 μM) for 2 h, and then challenged with or without LPS (1 μg/mL) for 1 h. (b–f and h–l) Quantification of relative protein expression was performed by densitometric analysis. Similar results were obtained from three independent experiments. The values presented are the means ± SEM.  < 0.05 and  < 0.01 versus control group; ^# < 0.05 and ^## < 0.01 versus LPS group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)